Amgen enters the first week of June with the defensive options tone that defined late May now visibly fading — while the short rebuild that had been running since mid-April appears to have lost momentum.
The clearest change from last week's setup is in options. The put/call ratio has dropped to 0.81, more than one standard deviation below its 20-day mean of 0.88. That is a sharp reversal from the defensive positioning flagged in the prior note, when the ratio had climbed above 1.0. Options traders who were paying up for downside protection a week ago have pulled back. The ratio is now closer to the call-heavy end of its 52-week range, which spans 0.62 to 1.11. The defensive posture has, for now, unwound.
Short interest tells a story of stalled momentum rather than fresh aggression. After climbing steadily from mid-April lows through late May — when it had risen roughly 8% over the month — the pace has slowed. Short interest is now 2.4% of the free float, up just 0.6% on the day and 6.5% on the week, but still well below the peak levels seen in early May when it briefly touched 13.6 million shares. Borrowing costs have risen — up 27% over the past week to 0.56% annualised — but remain firmly in "easy borrow" territory. Availability is extraordinarily loose at over 7,000%, meaning there is no lending constraint on new short positions. The rising cost without a corresponding availability crunch suggests incremental demand rather than a structural squeeze. The ORTEX short score has ticked higher across the past ten sessions, reaching 36.7, but that remains a modest reading in absolute terms.
The Street's view on Amgen is cautiously constructive but lacks conviction. The consensus rating is buy, with a mean price target of $352 against a current price of $328 — roughly 7% implied upside. The most recent analyst move came from Piper Sandler in mid-May, trimming its target modestly to $427 while keeping an Overweight rating. That followed Guggenheim and Truist both nudging targets lower in early May. Morgan Stanley, which raised its Equal-Weight target to $326 in April, now has a target that essentially mirrors the current share price. The bull case centres on Uplizna's rare-disease potential and pipeline depth. The bear case is more pressing near-term: Enbrel erosion, biosimilar pressure on Repatha, and questions about whether recent acquisitions will fill the revenue gap from patent expirations. The EV/EBITDA multiple at 10.3x has drifted lower over the past 30 days, while the P/E at 14.4x is broadly flat on the month. Factor scores are undistinguished — EPS surprise ranks in the 27th percentile, EPS momentum is near median, and the dividend score is the standout at the 98th percentile, reflecting Amgen's consistent yield.
The insider picture warrants a brief note. On May 7, nine senior executives — including the CFO, CTO, and Chief Scientific Officer — all sold shares on the same day at $331, each in small quantities with low trade-significance scores. The cluster is consistent with a pre-planned trading window rather than a conviction-driven sell-off, and the 90-day net insider position is actually slightly positive at roughly 17,600 shares. No alarm there, but the lack of any purchasing activity at current levels means insiders are not visibly endorsing the stock at the low-$300s.
Across the peer group, the sector-wide softness is notable. GILD fell 4.6% on the week, REGN dropped 5.0%, INCY lost 5.0%, and VRTX slid 2.5%. Amgen's 2.3% weekly decline is relatively contained within that group — a mild relative outperformance in what has been a difficult week for large-cap biotech.
The next scheduled earnings release is August 4. Between now and then, the key variables to watch are whether short interest continues its slow rebuild as the borrow cost rises, and whether the options market's sudden shift back toward calls reflects genuine re-rating momentum or simply a pause before the next leg of defensive repositioning.
See the live data behind this article on ORTEX.
Open AMGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
